147 related articles for article (PubMed ID: 31600485)
1. In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates.
Jiang J; Wang L; Kou X; Liu Z; Huang M; Li H; Wu C
Exp Eye Res; 2020 Jan; 190():107823. PubMed ID: 31600485
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2.
Jiang J; Xu K; Wang L; Xin W; Zhao G; Huang M; Li S; Luan X; Fang J
Eur J Pharm Sci; 2018 Aug; 121():251-259. PubMed ID: 29715501
[TBL] [Abstract][Full Text] [Related]
3. Role of the Fc Region in the Vitreous Half-Life of Anti-VEGF Drugs.
Joo K; Park SJ; Choi Y; Lee JE; Na YM; Hong HK; Park KH; Kim HM; Chung JY; Woo SJ
Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4261-4267. PubMed ID: 28850637
[TBL] [Abstract][Full Text] [Related]
4. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.
Shen J; Durairaj C; Lin T; Liu Y; Burke J
Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1056-66. PubMed ID: 24448267
[TBL] [Abstract][Full Text] [Related]
5. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.
Park SJ; Oh J; Kim YK; Park JH; Park JY; Hong HK; Park KH; Lee JE; Kim HM; Chung JY; Woo SJ
Eye (Lond); 2015 Apr; 29(4):561-8. PubMed ID: 25592118
[TBL] [Abstract][Full Text] [Related]
6. Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model.
Park SJ; Choi Y; Na YM; Hong HK; Park JY; Park KH; Chung JY; Woo SJ
Invest Ophthalmol Vis Sci; 2016 May; 57(6):2612-7. PubMed ID: 27258433
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit.
Li H; Lei N; Zhang M; Li Y; Xiao H; Hao X
Exp Eye Res; 2012 Apr; 97(1):154-9. PubMed ID: 21933673
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina.
Yang QH; Zhang Y; Jiang J; Wu MM; Han Q; Bo QY; Yu GW; Ru YS; Liu X; Huang M; Wang L; Zhang XM; Fang JM; Li XR
Int J Ophthalmol; 2018; 11(6):935-944. PubMed ID: 29977804
[TBL] [Abstract][Full Text] [Related]
10. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys.
Yu DA; You M; Ji WW; Lu Y; Liu B; Yan SS
Toxicol Lett; 2018 Aug; 292():73-77. PubMed ID: 29709424
[TBL] [Abstract][Full Text] [Related]
12. Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats.
Jakubiak P; Alvarez-Sánchez R; Fueth M; Broders O; Kettenberger H; Stubenrauch K; Caruso A
Mol Pharm; 2021 Jun; 18(6):2208-2217. PubMed ID: 34014104
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
Furrer E; Berdugo M; Stella C; Behar-Cohen F; Gurny R; Feige U; Lichtlen P; Urech DM
Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):771-8. PubMed ID: 18757508
[TBL] [Abstract][Full Text] [Related]
15. Ocular and systemic pharmacokinetics of BI-X, a nanobody targeting VEGF and Ang-2, after intravitreal dosing in cynomolgus monkeys - Evidence for half-life extension by albumin.
Fuchs H; Chen LZ; Low S; Yu H
Exp Eye Res; 2021 Apr; 205():108486. PubMed ID: 33571529
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
[TBL] [Abstract][Full Text] [Related]
17. Extended Pharmacokinetic Model of the Intravitreal Injections of Macromolecules in Rabbits. Part 2: Parameter Estimation Based on Concentration Dynamics in the Vitreous, Retina, and Aqueous Humor.
Lamminsalo M; Karvinen T; Subrizi A; Urtti A; Ranta VP
Pharm Res; 2020 Oct; 37(11):226. PubMed ID: 33094404
[TBL] [Abstract][Full Text] [Related]
18. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys.
Ren X; Li J; Xu X; Wang C; Cheng Y
Exp Eye Res; 2016 Apr; 145():352-358. PubMed ID: 26919788
[TBL] [Abstract][Full Text] [Related]
19. A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy.
Le KN; Gibiansky L; Good J; Davancaze T; van Lookeren Campagne M; Loyet KM; Morimoto A; Jin J; Damico-Beyer LA; Hanley WD
J Pharmacol Exp Ther; 2015 Nov; 355(2):288-96. PubMed ID: 26359312
[TBL] [Abstract][Full Text] [Related]
20. Single ocular injection of a sustained-release anti-VEGF delivers 6months pharmacokinetics and efficacy in a primate laser CNV model.
Adamson P; Wilde T; Dobrzynski E; Sychterz C; Polsky R; Kurali E; Haworth R; Tang CM; Korczynska J; Cook F; Papanicolaou I; Tsikna L; Roberts C; Hughes-Thomas Z; Walford J; Gibson D; Warrack J; Smal J; Verrijk R; Miller PE; Nork TM; Prusakiewicz J; Streit T; Sorden S; Struble C; Christian B; Catchpole IR
J Control Release; 2016 Dec; 244(Pt A):1-13. PubMed ID: 27810558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
